Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  New England Journal of Medicine

• Publication date

  2001-04-05

• Fields of study

  Medicine

• Identifiers
  DOI 10.1056/NEJM200104053441401PMID 11287972
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.

  2001cited by this paper
• Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia.

  2000cited by this paper
• Commentary on and reprint of Nowell PC, Hungerford DA, A minute chromosome in human chronic granulocytic leukemia, in Science (1960) 132:1497

  2000cited by this paper
• An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology.

  1999cited by this paper
• Chronic myeloid leukemia.

  1999cited by this paper
• The biology of chronic myeloid leukemia.

  1999cited by this paper
• Structural Requirements for Function of the Crkl Adapter Protein in Fibroblasts and Hematopoietic Cells

  1998cited by this paper
• The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells.

  1997cited by this paper
• Direct binding of CRKL to BCR-ABL is not required for BCR-ABL transformation.

  1997cited by this paper
• Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis.

  1997cited by this paper
• Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells

  1996cited by this paper
• Tyrosine phosphorylation of CRKL in Philadelphia+ leukemia.

  1994cited by this paper
• Identification of CRKL as the constitutively phosphorylated 39-kD tyrosine phosphoprotein in chronic myelogenous leukemia cells.

  1994cited by this paper
• Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia.

  1994cited by this paper
• rel Is rapidly tyrosine-phosphorylated following granulocyte-colony stimulating factor treatment of human neutrophils.

  1994cited by this paper
• Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL.

  1990cited by this paper
• Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

  1990cited by this paper
• Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome.

  1990cited by this paper
• Acute leukaemia in bcr/abl transgenic mice

  1990cited by this paper
• A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa Staining

  1973cited by this paper
• A minute chromosome in human chronic granulocytic leukemia

  1960cited by this paper

• Bioengineered heart valves for personalized therapy: advances in manufacturing and clinical challenges

  2026cites this paper
• Impact of Beta-Thalassemia Trait on Clinical Outcomes and Treatment Response in Chronic Myeloid Leukemia.

  2026cites this paper
• Subsequent Primary Neoplasms and Mortality Among Survivors of Childhood Cancer in Alberta, Canada.

  2026cites this paper
• Targeted therapy in chronic myeloid leukemia with imatinib: A retrospective hospital-based study in Georgia

  2026cites this paper
• LocAlign: Local Protein Structural Alignment with Geometric Deep Learning

  2026cites this paper
• Evolving Therapeutic Algorithms in Chronic Myeloid Leukemia: Integrating Efficacy, Safety, and Survivorship.

  2026cites this paper
• Golgi Retention and Oncogenic Signaling of KIT Tyrosine Kinase in Gastrointestinal Stromal Tumor.

  2026cites this paper
• c-Abl controls early embryonic morphogenesis through YAP/p73-dependent regulation of trophectoderm and inner cell mass lineages

  2026cites this paper
• The Evolving Role of Second- and Third-Generation Tyrosine Kinase Inhibitors in Gastrointestinal Malignancies: Advances in Targeted Therapy with Sunitinib, Regorafenib, and Avapritinib

  2026cites this paper
• Skeletal effects of nilotinib on prepubertal and pubertal rats

  2026cites this paper
• Advances in cancer genomics and precision oncology

  2025cites this paper
• Analysis of Pan-Specific Inhibitors of Oncogenic Mutant Forms of KRAS GTPase.

  2025cites this paper
• Dual BCR::ABL1 Inhibition Shows Promise in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

  2025cites this paper
• SplitFusion enables ultrasensitive gene fusion detection and reveals fusion variant-associated tumor heterogeneity

  2025cites this paper
• Computational Insights into the Polypharmacological Landscape of BCR-ABL Inhibitors: Emphasis on Imatinib and Nilotinib

  2025cites this paper
• Fusion transcripts landscape in hepatocellular carcinoma and potential impact on the expression of fusion partners

  2025cites this paper
• Impact of First- and Second-Generation Tyrosine Kinase Inhibitors on the Development of Graft-Versus-Host Disease in Individuals with Chronic Myeloid Leukemia: A Retrospective Analysis on Behalf of the Polish Adult Leukemia Group

  2025cites this paper
• Pulmonary Infections in Patients Receiving Corticosteroids and Other Immunomodulators

  2025cites this paper
• Insights into Treatment-Free Remission (TFR) outcomes in Chronic Myeloid Leukaemia (CML) – a tertiary centre experience in Malaysia

  2025cites this paper
• Cross-pollination of two specialties: potential repurposing of cancer and cardiovascular drugs for the benefit of the other.

  2025cites this paper
• Bosutinib-Induced Pleural Effusion—Class Effect and Cross-Intolerance to All Tyrosine Kinase Inhibitors

  2025cites this paper
• An overview of recent advancements in targeted cancer therapies and their potential clinical impact.

  2025cites this paper
• Twenty‐five years without progress: The enduring challenge of soft tissue sarcomas

  2025cites this paper
• Ph-Positive Acute Lymphoblastic Leukemia - 25 Years of Progress.

  2025cites this paper
• Uncovering the Understanding of the Concept of Patient Similarity in Cancer Research and Treatment: Scoping Review

  2025cites this paper
• AI-Driven Identification and Validation of RXFP1 as a CML Biomarker Using Gene Expression and Integrated GUI Tools

  2025cites this paper
• Genomic Medicine: Applications in Disease Prevention and Treatment

  2025cites this paper
• Temporal changes in survival among adult patients with chronic myeloid leukemia in the period 1995–2022—a Danish nationwide population-based register study

  2025cites this paper
• KF1601, a dual inhibitor of BCR::ABL1 and FLT3, overcomes drug resistance in FLT3+ blast phase chronic myeloid leukemia

  2025cites this paper
• Stromal KITL/SCF Maintains Pancreas Tissue Homeostasis and Restrains Tumor Progression

  2025cites this paper
• Bibliometric analysis and recent trends on tyrosine kinase inhibitors in leukemia

  2025cites this paper
• The GF-NEO discovery platform unveils a [KQE][DG] sequence motif within fusion neoantigens in pediatric cancer

  2025cites this paper
• Real-world analysis of cardiovascular adverse events and risk factors after immune checkpoint inhibitor therapy

  2025cites this paper
• Potential signaling pathways, biomarkers, natural drugs, and chronic myeloid leukemia therapeutics

  2025cites this paper
• Comprehensive resistance profiling of chronic myeloid leukaemia associated ABL1 variants against five tyrosine kinase inhibitors using prime editing.

  2025cites this paper
• Direct Targeting of Gene Regulators by Iridium(III) and Rhodium(III) Complexes

  2025cites this paper
• A functional map of CDK-drug interactions at single amino acid resolution

  2025cites this paper
• Imatinib in Targeted Therapy: Advances in Biomedical Applications and Drug Delivery Systems

  2025cites this paper
• Evaluation of leukemic stem cell (CD26 +) in chronic myeloid leukemia patients with different molecular responses and in treatment-free remission

  2025cites this paper
• Analysis of error profiles of indels and structural variants in deep-sequencing data

  2025cites this paper
• Serial Magnetic Resonance Imaging Follow-up of a Chihuahua with Meningoencephalitis of Unknown Origin Treated with Prednisolone and Imatinib: A Case Report

  2025cites this paper
• Hematologic malignancies and an overview of emerging therapies for hematologic malignancies: a systematic review.

  2025cites this paper
• Tyrosine Kinase Inhibitor Therapy Enhances Stem Cells Profile and May Contribute to Survival of Chronic Myeloid Leukemiastem Cells

  2025cites this paper
• Imatinib and the dawn of precision cancer therapy

  2025cites this paper
• Tumor-specific surface marker–independent targeting of tumors through nanotechnology and bioorthogonal glycochemistry

  2025cites this paper
• Considerations on the Dose and Schedule of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: Does Dose Matter?

  2025cites this paper
• Next-generation sequencing for guiding matched targeted therapies in people with relapsed or metastatic cancer.

  2025cites this paper
• Proximity-induced membrane protein degradation for cancer therapies.

  2025cites this paper
• BCR-ABL: The molecular mastermind behind chronic myeloid leukemia.

  2025cites this paper
• WITHDRAWN: OncoStratifier: Stratifying Oncogene-addicted Cohorts By Drug Response

  2025cites this paper
• Fast and sensitive detection of targeted gene fusions using frequency minimizers and fuzzy pattern matching with Fuzzion2

  2025cites this paper
• MiR-92a-1-5p contributes to cellular proliferation and survival in chronic myeloid leukemia and its inhibition enhances imatinib efficacy

  2025cites this paper
• Chemical Adaptation in Drug Discovery: The Medicinal Chemistry Journey of Olverembatinib and Limertinib in Overcoming Kinase Drug Resistance.

  2025cites this paper
• Serum SERS Analysis Reveals Amino Acid- and Protein-Associated Vibrational Features for Subtype Identification in Acute Lymphoblastic Leukemia.

  2025cites this paper
• Expert consensus definition of treatment intolerance in chronic myeloid leukemia in chronic phase

  2025cites this paper
• Paired Tumor/Normal Sequencing Identifies a SEPT9::ABL1 Fusion in a Child With T‐Cell Lymphoblastic Lymphoma

  2025cites this paper
• Thiostrepton Suppresses the Progression of Rhabdomyosarcoma by Inhibiting the PI3K‐AKT Signaling Pathway

  2025cites this paper
• Multi-targeted, NOT gated CAR-T cells as a strategy to protect normal lineages for blood cancer therapy

  2025cites this paper
• The role of METTL14 in the progression of chronic myeloid leukemia

  2025cites this paper
• Combining Multiplexed CRISPR/Cas9-Nickase and PARP Inhibitors Efficiently and Precisely Targets Cancer Cells

  2025cites this paper
• Tumour-agnostic kinase inhibitors

  2025cites this paper
• Host directed immunotherapy for chronic infections and cancer.

  2025cites this paper
• [Efficacy and safety of venetoclax combined with tyrosine kinase inhibitors and reduced-dose chemotherapy in 13 cases of minimal residual disease-positive and relapsed/refractory Ph(+) acute lymphoblastic leukemia].

  2025cites this paper
• A Review on Applications and Evolution of Molecular Markers in Pharmaceutical Sciences

  2025cites this paper
• Optimization of pharmaceutical research and development by early-phase assessment of investigational medicinal products.

  2025cites this paper
• Modulatory Effects of Caffeine on Imatinib Binding: A Molecular Docking Study Targeting CYP3A4

  2025cites this paper
• Tyrosine phosphoproteome profiling identifies cell-intrinsic signals limiting the efficacy of tyrosine kinase inhibitor therapies

  2025cites this paper
• Molecular Milestones and Survival Outcomes of Ponatinib Treatment in Patients With Chronic Myeloid Leukemia and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia: A Real-World Analysis.

  2025cites this paper
• In vivo cancer modeling using mouse models.

  2025cites this paper
• Strategies for the drug development of cancer therapeutics

  2025cites this paper
• Risk of cardiovascular and cerebrovascular diseases in patients with myeloid neoplasms: results from 1.8 million inhabitants of North-West Italy.

  2025cites this paper
• Advanced cancer therapy: unlocking the potential of small molecule inhibitors.

  2025cites this paper
• A tour of leukemia progress in 2025, viewed through the MD Anderson leukemia research lens

  2025cites this paper
• Integrating functional genomics and proteomics identifies Folate Carrier SLC19A1 as a predictor of pralatrexate sensitivity in T-cell lymphoma

  2025cites this paper
• Cracking the Resistance Code:The Molecular Reclassification of Cancer and Precision Therapy Strategies.

  2025cites this paper
• First-line tyrosine kinase inhibitor response in chronic myeloid leukemia: A retrospective study from Iraqi Kurdistan

  2025cites this paper
• Pathway-Specific Therapeutic Modulation of Melanoma: Small-Molecule Inhibition of BRAF–MEK and KIT Signaling in Contemporary Precision Oncology with a Special Focus on Vemurafenib, Trametinib, and Imatinib

  2025cites this paper
• Fusion transcriptome landscape in glioblastoma: Incidence and therapeutic implications

  2025cites this paper
• G protein-coupled receptor digital twins for precision and personalized medicine

  2025cites this paper
• The Global Burden of Leukemia, 1990–2021: A Systematic Analysis of Prevalence, DALYs, and Risk Factors From the Global Burden of Disease Study

  2025cites this paper
• Stereo cell: A new approach to the next generation of clinical precision medicine

  2025cites this paper
• Interpreting the functional impact of genetic variants: The need for context qualifiers.

  2025cites this paper
• Bone Marrow Edema and Tyrosine Kinase Inhibitors Treatment in Chronic Myeloid Leukemia

  2025cites this paper
• Improving quality of life for patients with chronic myeloid leukemia through supportive care, low-dose therapy, switching, and treatment-free remission.

  2025cites this paper
• Challenges and opportunities for oncology drug repurposing informed by synthetic lethality

  2025cites this paper
• The Role of the Bone Marrow Microenvironment in Leukemic Stem Cell Resistance: Pathways of Persistence and Selection.

  2025cites this paper
• Asciminib resistance of a new BCR::ABL1 p.I293_K294insSSLRD mutant detected in a Ph + ALL patient

  2025cites this paper
• A Review on Medicinal Approaches of Novel Imatinib Derivatives.

  2025cites this paper
• Target identification and validation in research

  2024cites this paper
• Modeling cancer dependency with deep graph models

  2024cites this paper
• A safety review of tyrosine kinase inhibitors for chronic myeloid leukemia

  2024cites this paper
• Late Cardiotoxicity from the Tyrosine Kinase Inhibitor, Dasatinib: Pleural Effusions, Pulmonary Arterial Hypertension, and Right Heart Failure

  2024cites this paper
• Physical exercise recommendations for patients with chronic myeloid leukemia based on individual preferences identified in a large international patient survey study of the East German Study Group for Hematology and Oncology (OSHO #97)

  2024cites this paper
• Discovery of a Covalent Inhibitor Selectively Targeting the Autophosphorylation Site of c-Src Kinase.

  2024cites this paper
• Structural characterization of methylation-independent PP2A assembly guides alphafold2Multimer prediction of family-wide PP2A complexes

  2024cites this paper
• Zinc as a potential regulator of the BCR-ABL oncogene in chronic myelocytic leukemia cells.

  2024cites this paper
• Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials

  2024cites this paper
• Glycaemic abnormalities induced by small molecule tryosine kinase inhibitors: a review

  2024cites this paper
• Navigating between Scylla and Charybdis: A roadmap to do better than Pola-RCHP in DLBCL.

  2024cites this paper
• The impact of the BCR-ABL oncogene in the pathology and treatment of chronic myeloid leukemia.

  2024cites this paper